AMRX in the 13F filings
Amneal Pharmaceuticals Inc · CUSIP 03168L105
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 14 Feb 2024
- up to 45 days after the quarter end
- Managers listing it
- 1
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 1 listed it in both
- Shares listed
- 83,393
- combined, among listed positions
- Reported value
- $506k
- combined, at the quarter end
Among the 93 comparable managers: 0 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing AMRX in Q4 2023
1 of 1 holder
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Caxton Associates LLP | 83,393 | $506k | under 0.1% | Trimmed | -36,887 | 14 Feb 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
No increase among listed positions.
Reductions
- Caxton Associates LLPexisting position · 83,393 shares now-36,887
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2018 | 3 | $226m | n.a. | n.a. |
| Q3 2018 | 6 | $588m | n.a. | n.a. |
| Q4 2018 | 3 | $514m | n.a. | n.a. |
| Q1 2019 | 3 | $514m | n.a. | n.a. |
| Q2 2019 | 1 | $24m | n.a. | n.a. |
| Q4 2020 | 1 | $2k | n.a. | n.a. |
| Q1 2021 | 3 | $30m | n.a. | n.a. |
| Q2 2021 | 2 | $9.3m | n.a. | n.a. |
| Q3 2021 | 2 | $20m | n.a. | n.a. |
| Q4 2021 | 2 | $16m | n.a. | n.a. |
| Q1 2022 | 2 | $13m | n.a. | n.a. |
| Q2 2022 | 1 | $11m | n.a. | n.a. |
| Q3 2023 | 2 | $879k | n.a. | n.a. |
| Q4 2023 | 1 | $506k | 0 | 1 |
| Q1 2024 | 2 | $4.7m | 2 | 0 |
| Q2 2024 | 2 | $13m | 2 | 1 |
| Q3 2024 | 3 | $23m | 3 | 0 |
| Q4 2024 | 2 | $14m | 2 | 1 |
| Q1 2025 | 4 | $39m | 4 | 0 |
| Q2 2025 | 3 | $28m | 2 | 1 |
| Q3 2025 | 4 | $37m | 2 | 2 |
| Q4 2025 | 5 | $85m | 17 | 14 |
| Q1 2026 | 7 | $78m | 14 | 19 |
| Q2 2026 | 4 | $101m | 11 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
AMRX and LLY →AMRX and JNJ →AMRX and VRTX →Choose a stock to compare with AMRX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own AMRX, latest filings →Back to the 13F Explorer →